Clinical-stage biotechs tend to be judged on one question — can the lead asset reach a pivotal trial — and Alterity Therapeutics (ASX:ATH) sits at precisely that juncture. The company, which operates from Melbourne and San Francisco, says it is preparing a Phase 3 pivotal study of ATH434 in multiple system atrophy, a rare and rapidly progressive neurodegenerative disease. Two events in early September 2026 sharpen the picture: a $4.2 million share issue and a presentation slot at a United States healthcare investor conference.

Company Overview

Alterity Therapeutics has been listed on the ASX since March 2000 and remains pre-revenue. Its lead candidate, ATH434, targets the underlying pathology of multiple system atrophy and related Parkinsonian disorders. Behind it sits what the company calls a broad drug discovery platform generating patentable compounds aimed at mechanisms of neurological disease. Operations span Melbourne and San Francisco, California.

On 8 September 2026 Alterity applied for Quotation of 8,400,000 fully paid ordinary shares issued at A$0.50 each, raising A$4.2 million that the company described as additional working capital. The issue was made under exception 10 of ASX Listing Rule 7.2 and so did not require Shareholder approval. MST Financial Services received an Underwriting fee of 7 per cent of gross proceeds, and a cleansing notice under section 708A was lodged the same day. After quotation the company has 229,100,845 quoted ordinary shares on issue. Chief executive David Stamler was also scheduled to present at the Cantor Global Healthcare Conference on 11 September 2026.

Alterity states that ATH434 has demonstrated clinically meaningful efficacy in a randomised, double-blind, placebo-controlled Phase 2 trial in multiple system atrophy, and that positive findings also came from an open-label Phase 2 study in participants with advanced disease. On that basis the company says it is preparing to initiate a Phase 3 pivotal trial. Change of director's interest notices for two directors were lodged on 2 September 2026.

Financial and Operational Position

On a trailing twelve-month basis to 31 December 2025, Alterity held cash and equivalents of about A$49.2 million, up from A$33.16 million at 30 June 2025. Total Assets were A$56.92 million and shareholders' Equity A$54.27 million, with total Debt negligible at roughly A$0.1 million.

That cash position reflects capital raising rather than trading. Shares on issue rose from about 104.9 million to 217.51 million over the comparable period, and the September 2026 issue lifts the quoted count to 229.1 million. As a developer without product sales, Alterity funds its programmes from equity.

What Investors May Watch Next

The central item is confirmation of the Phase 3 design, regulatory alignment and start timing for ATH434. Quarterly Appendix 4C filings will show cash burn and indicate how far the Balance Sheet stretches against a pivotal trial budget, and whether further raisings follow September's issue. Partnering interest and any data presentations at medical meetings could also draw attention.

Risks

Phase 3 studies in neurodegeneration carry a high failure rate, and Phase 2 signals do not guarantee replication at scale. Multiple system atrophy is rare, which complicates recruitment and can extend timelines. Alterity has no revenue, so further dilution is a realistic prospect: shares on issue have more than doubled over recent reporting periods. Regulatory decisions, Manufacturing and competing programmes all sit outside the company's direct control.

Key Takeaways

September 2026 is less about a single announcement for Alterity than about positioning. A topped-up balance sheet, an appearance in front of United States specialist healthcare investors, and a stated intention to move ATH434 into a pivotal trial all point in the same direction. The key story ASX investors may be watching is whether the company can fund and launch that Phase 3 without eroding existing holders further.